BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dermavon Holdings readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Dermavon Holdings's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07465120-1339@assetmemo.bio
DTSTAMP:20261121T005933Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:CMS-D001: Phase 2 readout est. (NCT07465120)
DESCRIPTION:CMS-D001\, phase 2\, Atopic Dermatitis.\nStudy: A Multicenter\,
  Randomized\, Double-Blind\, Placebo-Controlled\, Phase Ⅱ Clinical Study
  to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Mo
 derate to Severe Atopic Dermatitis\nEstimated primary completion: 31 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cms-d001#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746512
 0
URL:https://assetmemo.bio/drug/cms-d001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432854-1339@assetmemo.bio
DTSTAMP:20261121T005933Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:CMS-D001: Phase 2/3 readout est. (NCT07432854)
DESCRIPTION:CMS-D001\, phase 2/3\, Psoriasis.\nStudy: A Clinical Study Eval
 uating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adu
 lt Patients With Moderate to Severe Plaque-type Psoriasis\nEstimated prima
 ry completion: 29 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cms-d001#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07432854
URL:https://assetmemo.bio/drug/cms-d001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
